Editorial Policy

        Originality, superior scientific quality, and appeal to a multidisciplinary audience are the primary requirements for publication. Experimental details should sufficiently substantiate research articles.

 

Types of Papers:

1. Full-length Research Papers: Translational Health Sciences welcomes original research addressing issues relevant to Pharmaceutical Sciences, Physiotherapy,  and Veterinary Medicine. Submissions should present novel findings and contribute to the advancement of the field.
2. Review Articles: Translational Health Sciences Journal publishes concise reviews on topics of interest including Pharmaceutical Sciences, Physiotherapy, and Veterinary Medicine. Reviews must offer balanced interpretations and state-of-the-art accounts of subjects relevant to investigators in the field. Reviews undergo rigorous peer review and should propose new interpretations or experimental approaches.

Manuscript Preparation and Submission

"Your paper is your way in the first submission". When the authors are asked to revise their manuscript, they should adhere to the journal guidelines in the revised version.

Title page

      Should include the following details:

• Article title: should be concise, and informative, with no abbreviations, unless they are widely understood.
• Author(s) name(s).
• Affiliations. The affiliation address refers to where the work was carried out. Affiliations are identified as a lower-case superscript letter immediately after the author's name.
• The corresponding author who will handle correspondence during submission, evaluation, publication, and post-publication.

Abstract

• The goal of your study, key findings, and important conclusions should all be succinctly stated in the abstract. All abbreviations must be spelled out fully when first mentioned in the abstract or body of the article. Abstracts are limited to 300 words. Immediately following the abstract, authors must provide up to 6 keywords for indexing purposes, using American spelling.

Introduction Section

• Clearly state the hypothesis, related articles, and primary endpoints of the study in the introduction.

Materials and Methods Section:

• If human tissues or fluids were used, confirm Institutional Review Board (IRB) approval.
• Provide details on animals used, including species, strain, and ethical approval from the ethical committee of the affiliated institution.
• Justify the examination of a single cell line if applicable.
• Specify the source and passage number of cell lines, ensuring authentication.
• Present chemical structures of new compounds or reference them in peer-reviewed literature.
• Indicate the sources of all materials used, including validation of antibodies and interference RNA.
• Justify the selection of concentrations, doses, routes, and frequency of compound administration.
• Include quantified results of concentration- and dose-response experiments.
• Ensure group sizes are similar and indicated.
• Define criteria for excluding data from analysis prospectively.
• Ensure blinding of the investigator responsible for data analysis.
• Present reported data as means +/- standard deviation, indicating replicates and statistical significance threshold.

Results, and Discussion Section(s):

• Clearly state the results, primary conclusions and implications, addressing any secondary endpoints.
• For western blots, include appropriate controls, replication data, and statistical analyses.
• Adhere to MIQE guidelines for PCR and RT-PCR, including the inclusion of reference standards.
• Acknowledge limitations or alternative interpretations of findings.

Conflict of Interest/Financial Support:

• Include a conflict of interest statement.
• List all funding organizations, if present, in a separate section.

Acknowledgments

• Acknowledgments must be listed in a separate section at the end of the article before the references. They should include the names of individuals, and organizations, that aided in the work.

Ethics in Publishing:

Studies in Humans

         Research articles involving the use of human subjects should be carried out following the World Medical Association Declaration of Helsinki "Ethical principles for medical research involving human subjects".

 

Studies in animals

          All animal experiments should comply with "Animal Research: Reporting of In Vivo Experiments" (ARRIVE guidelines). Studies should be carried out with respect to "Guidance on the operation of the Animals (Scientific Procedures) Act 1986" and associated guidelines.

 

Be careful,

• Disclose any use of generative AI and AI-assisted technologies in writing processes.
• Declaration of Generative AI and AI-assisted Technologies in the Writing Process
• During preparation, if generative AI or AI-assisted technologies were utilized, provide details on the tool/service used, and the reason for use, and confirm manual review and editing of content.
• Confirm that the submitted work has not been previously published or under consideration elsewhere.

Use of Inclusive Language:

• Ensure the use of inclusive language throughout the manuscript.
• Reporting Sex- and Gender-based Analyses
• Integrate sex and gender-based analyses into research design and reporting where applicable.

Author Contributions:

• Provide co-author contributions according to the CRediT roles.

Changes to Authorship:

• Requests for changes to authorship should be made before acceptance and require approval from all authors.

Copyright:

• Upon acceptance, authors must complete the Journal Publishing Agreement.
• By adhering to these guidelines, authors can ensure a smooth submission process and facilitate rigorous review for publication in the Translational Health Sciences Journal. 

Author Rights:

• As an author, you (or your employer or institution) retain certain rights to reuse your work. For more detailed information, please refer to the Author Rights section on our website.
• Discover how you can responsibly share your research published in Elsevier journals. Visit our website for more information.

Submission:

• All articles must be submitted online through our submission portal. The manuscripts must be uploaded as separate editable files (e.g., text and tables in Word or LaTeX, and figures in common artwork formats). For detailed instructions, please refer to our submission guidelines.

Institutional Email Address:

• The institutional email address MUST be included in the registered profile of the corresponding author in our online submission system. Alternatively, the submission must be accompanied by a separate statement in English on institutional letterhead, signed by an official responsible for research activities for the institute from which the manuscript originates, verifying the corresponding author's affiliation. The statement must also include the official's institutional email address and full contact information. 

Suggesting Reviewers:

• Authors are encouraged to submit the names and institutional email addresses of several potential reviewers. However, please avoid suggesting reviewers who are colleagues or who have co-authored or collaborated with you in the last three years. Editors do not invite reviewers who have potential competing interests with the authors. Additionally, please suggest diverse candidate reviewers located in different countries/regions from the author group. Consider other diversity attributes such as gender, race, ethnicity, and career stage. Note that the editor ultimately decides whether or not to invite your suggested reviewers.

Categories:

• Authors must indicate on the title page which category best describes their work. The categories include Physiotherapy, Pharmaceutical Sciences, and Veterinary Medicine.

Manuscript Preparation:

Language

• Authors are responsible for ensuring that the article is written in clear English. Manuscripts must be double-spaced in single-column format with 1" or 25 mm margins. Size 12 (point) Times New Roman or Arial font is preferred. The article must be divided into clearly defined and numbered sections, including Introduction, Materials and Methods, Results, Discussion, and References.

Nomenclature and Abbreviations:

• Receptor and ion channel nomenclature must conform to the guidelines of the Committee on Receptor Nomenclature and Drug Classification of the International Union of Basic and Clinical Pharmacology (IUPHAR). Use only abbreviations generally accepted by the scientific community.

Cell Lines

• For consideration by the journal, a study must include an examination of two or more authenticated cell lines to verify results unless the use of a single cell line is adequately justified in the text. Cell line authentication requires specification of source, method of authentication, and passage number. 

Equations and Formulae

• Equations and formulae should be typed and numbered consecutively with Arabic numerals in parentheses on the right-hand side of the page if referred to explicitly in the text.

Footnotes

• Footnotes should be used sparingly and numbered consecutively throughout the text, listed separately at the end of the article. Do not include footnotes in the Reference list.

Figure Legends

• Illustrations must have captions listed separately from the figure in the submitted version of the work. Captions should be self-explanatory without the need to reference the accompanying text.

Tables

• All tables must be numbered consecutively in Arabic numerals and cited in the text in their order of appearance. They should appear individually on separate pages with brief, descriptive titles. Tables should not have vertical lines, and the number of horizontal lines should be minimized.

References

• Ensure that every reference cited in the text is in the reference list, and vice versa. Unpublished results and personal communications should not appear in the reference list. THS follows the Vancouver reference style (https://library.viu.ca/citing/vancouver).
• In-text references consist of consecutive numbers formatted in ^superscript and placed after the period.
• The Vancouver style uses the citation-sequence system, meaning that references at the end of the article are numbered in the order in which the corresponding citations appear in your text, rather than listed alphabetically by author.
• Use the "List of Title Word Abbreviations" (LTWA) for abbreviated journal names.

Research Data

• This journal requires and enables authors to share data that support their research publication when appropriate. Various ways to associate data with your article or make a statement about its availability are outlined on our research data page. 

After Acceptance

Online Proof Correction

• Authors are requested to provide proof corrections within two days of receiving the proof. Corresponding authors will receive an email with a link to our online proofing system.

These guidelines aim to ensure that manuscripts submitted to the Translational Health Sciences adhere to our standards and requirements.